Journal of Hepatocellular Carcinoma (Jan 2025)
A New Risk Score Based on Lipid Indicators for Patients with Advanced Hepatocellular Carcinoma
Abstract
Xing Wei,1 Ziwei Guo,2 Tingting Zhang,3 Jun Liang1 1Department of Medical Oncology, Peking University International Hospital, Beijing, People’s Republic of China; 2Department of Medicine, Double Crane Runchuang Technology (Beijing) Co., Ltd, Beijing, People’s Republic of China; 3Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory of Digestive Health, National Clinical Research Center for Digestive Diseases, Beijing, People’s Republic of ChinaCorrespondence: Jun Liang, Email [email protected]: The prognosis is extremely troubling in advanced hepatocellular carcinoma (HCC). Prognostic scores have been developed. Yet, the positive predictive values might appear inadequate. This retrospective study aimed to develop a quick and efficient risk score to assess prognosis and clinical response.Methods: A total of 391 hCC patients were enrolled and were divided into training and validation groups between 2015 and 2024. Patients were separated into high-risk and low-risk groups using X-tile software. Using the COX proportional risk model analysis method, we then created a risk score and examined them using Kaplan-Meier, time-dependent receiver operating characteristics (ROC) curve, and nomogram analysis.Results: In predicting overall survival (OS), free fatty acid/high-density lipoprotein cholesterol (FFHL), tumor size, and BCLC stage were independent prognostic variables. A new risk score was developed just above and used as a prognostic factor (p < 0.001 in the training and validation groups) and had a high time-dependent ROC for progress-free survival (PFS) (area under the curve [AUC] 0.688– 0.789 in the training group; AUC 0.592– 0.741 in the validation group) and OS (AUC 0.812– 0.918 in the training group; AUC 0.692– 0.981 in the validation group). In comparison to the best overall response (BOR), the score offered a more accurate evaluation of durable clinical benefit (DCB) (p < 0.001 in the training and validation group; p = 0.061 vs 0.001 in the training and validation group).Conclusion: A new score based on lipid markers is a useful tool for evaluating prognosis and distinguishing patients with DCB.Keywords: hepatocellular carcinoma, survival, prognosis, clinical response, risk score
